Study summary
A HER2 antibody-drug conjugate shrank tumors in 91.7% of HER2-high salivary cancers
91.7%response rate in HER2-high disease
What was tested
Trastuzumab rezetecan (SHR-A1811), an antibody that carries chemotherapy directly to HER2-positive cells, in advanced salivary gland carcinoma, with separate HER2-high and HER2-low groups.
What they found
- Tumors shrank in 91.7% of the HER2-high group, including 4 complete responses.
- In the HER2-low group, 45.5% responded, with median progression-free survival of 12.7 months.
- Serious side effects (mostly low white cell counts) occurred in 41.3%; lung inflammation was mild.
What it means
Suggests HER2 drug conjugates could work even when HER2 levels are only modest.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.